top

  Info

  • Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.

  Info

  • Utilizzare questo link per rimuovere la selezione effettuata.
Advances in Multiple Sclerosis Research-Series I
Advances in Multiple Sclerosis Research-Series I
Autore Matsoukas John
Pubbl/distr/stampa Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2021
Descrizione fisica 1 online resource (334 p.)
Soggetto topico Medicine
Soggetto non controllato adult-onset
agonist peptide
alemtuzumab
altered peptide ligands
antibodies against GluR3 peptide
antibody detection
antigen-specific immunotherapies
antigen-specific immunotherapy
astrocytes
autoimmune diseases
autoimmune encephalitis
autoimmunity
B cell receptor
biomarker
bupropion
carriers
cellular immunity
central nervous system
cerebral blood flow
chloroquine
clinical outcome
clinical outcomes
clinical phenotype
cognitive impairment
conformational analysis
conjugation
cranial nerve-VI palsy
craniopharyngioma
delivery methods
dendritic cells
diagnosis
diagnostic markers
disease-modifying treatments
drug delivery nanosystems
EAE
early-onset
ELISA
experimental autoimmune encephalomyelitis
fampridine
fractionated stereotactic radiation treatments
free light chains
Graphite/SiO2 electrode
gut microbiome
gut-brain axis
HPLC
Human Leucocyte Antigens
immune modulation
immune thrombocytopenic purpura
immunogenetics
immunoglobulins
immunomodulation
immunotherapeutics
immunotherapy
inflammation
intracortical facilitation
kappa
lipids
major depression
mannan
MBP83-99 peptide
memory T cells
metagenomics
microglia
MOG35-55
molecular dynamic
monoclonal antibodies
MS
MS drugs
multiple sclerosis
Multiple Sclerosis
multivalency
myelin basic protei
myelin oligodendrocyte glycoprotein
myelin peptides
N-glucosylated peptide epitopes
nanoparticles
nanotechnology
neurodegeneration
neuroimaging
neuropsychological assessment
NMR spectroscopy
NOE-constraints
oligodendrocytes
oxidative
peptide
peptides
plasma exchange
polymers
positron emission tomography
probiotics
proteolipid protein
S-adenosylmethionine
sample size
short intracortical inhibition
sphenoid sinusitis
ST285
Streptococcus thermophilus
T cell receptor
tDCS
tetraspanins
therapeutics
tolerance
tolerance induction
tolerogenic vaccines
trimolecular complex
TSPAN32
vaccine
vaccines
vitamin D3
voltammetry
walking disability
yoga
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Record Nr. UNINA-9910557385403321
Matsoukas John  
Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2021
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Diagnostic, Prognostic and Predictive Biological Markers in Bladder Cancer - Illumination of a Vision 2.0
Diagnostic, Prognostic and Predictive Biological Markers in Bladder Cancer - Illumination of a Vision 2.0
Autore Ecke Thorsten
Pubbl/distr/stampa Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2021
Descrizione fisica 1 online resource (240 p.)
Soggetto topico Medicine
Soggetto non controllato adjuvant chemotherapy
androgen receptor
BCG therapy
biomarker
biomarkers
BIRC5
bladder
bladder cancer
bladder cancer detection
cadmium exposure
cancer
chemotherapy
combination therapy
DNA methylation
drug resistance
ECRG4
ERBB2
F-actin
FGFR3
grade
heparan sulfate proteoglycans (HSPGs)
heparanase
histone demethylase
immunotherapy
invasion
ITIH5
JAK inhibitor
JAK-STAT pathway
KDM7A
KRT20
macrophage
metabolomics
Metallothionein
MIBC
miRNA
MS
muscle-invasive bladder cancer
n/a
NMR
non muscle invasive bladder cancer
non-invasive detection
oncolytic adenovirus
p53
personalized medicine
prediction
predictive biomarker
prognosis
proliferation
PTEN
quantitative PCR
RT-qPCR
somatic mutations
STAT3/5 inhibitor
survival
survivin
syndecan-1
TAGLN
TC-E 5002
telomerase
TERT promoter mutations
TERT promoter region
tumor marker
tumor markers
tumorigenesis
urinary biomarkers
urothelial cancer
urothelial carcinoma
urothelium
virotherapy
voided urine cytology
XVir-N-31
zinc transporter
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Record Nr. UNINA-9910557142003321
Ecke Thorsten  
Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2021
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
MS-DOS 4.0 / K.W. Christopher Jr., B.A. Feigenbaum, S.O. Saliga
MS-DOS 4.0 / K.W. Christopher Jr., B.A. Feigenbaum, S.O. Saliga
Autore Christopher, Ken W., , jR.
Pubbl/distr/stampa Milano : Tecniche Nuove, 1989
Descrizione fisica XIX, 540 p. ; 24 cm
Disciplina 005.1
Soggetto non controllato MS
ISBN 88-7081-533-1
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione ita
Record Nr. UNINA-990000846090403321
Christopher, Ken W., , jR.  
Milano : Tecniche Nuove, 1989
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Remedicalizing cannabis : science, industry, and drug policy / / Suzanne Taylor
Remedicalizing cannabis : science, industry, and drug policy / / Suzanne Taylor
Autore Taylor Suzanne <1909-2004, >
Edizione [1st ed.]
Pubbl/distr/stampa London, England : , : McGill-Queen's University Press, , [2022]
Descrizione fisica 1 online resource (305 pages)
Disciplina 362.295561
Collana Intoxicating Histories
Soggetto topico Cannabis - Government policy - Great Britain - History - 20th century
Cannabis - Government policy - Great Britain - History - 21st century
Cannabis - Therapeutic use - Great Britain - History - 20th century
Cannabis - Therapeutic use - Great Britain - History - 21st century
Marijuana industry - Great Britain - History - 20th century
Marijuana industry - Great Britain - History - 21st century
Soggetto non controllato ACMD
CBD
CBMPs
Cannabinoids
Griffith Edwards
INCB
MS
Sativex
Science
Sir William Paton
THC
World Health Organization
bio tech industry
boundary substance
cannabis oil
clinical trials
committees
drug policy
drugs
epilepsy
exchange
expert advice
illicit substances
industry
international agencies
knowledge
marijuana
misuse
oral history
patient access
pharmaceutical
pharmacology
phytopharmacy
plant based medicine
policy
pot
psychopharmacology
tinctures
uncertainty
user activism
ISBN 0-2280-1350-X
0-2280-1349-6
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Front Matter -- Contents -- Figures -- Acknowledgements -- Abbreviations -- Introduction -- Understanding Cannabis: Pharmacology, Laboratory Research, and Drug Control, 1964–82 -- Cannabis in the Clinic: Clinical Pharmacology and the Therapeutic Applications of Cannabis, 1973–82 -- Evidence-Based Policy? The Development of Expert Committees, 1972–82 -- Industrializing Cannabis: The Pharmaceutical Industry and the Remedicalization of Cannabis, 1973–2001 -- Forces of Necessity: Lay Advocacy and the Remedicalization of Cannabis, 1973–2001 -- Establishing Therapeutic Cannabis: The Role of Expert Advice, 1997–2001 -- From Anecdotal to Evidence-Based Medicine: The Role of Clinical Trials, 1995–2005 -- Accessing Cannabis-Based Medicinal Products, 2009–21 -- Conclusion -- Notes -- Bibliography -- Index
Record Nr. UNINA-9910795726603321
Taylor Suzanne <1909-2004, >  
London, England : , : McGill-Queen's University Press, , [2022]
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Remedicalizing cannabis : science, industry, and drug policy / / Suzanne Taylor
Remedicalizing cannabis : science, industry, and drug policy / / Suzanne Taylor
Autore Taylor Suzanne <1909-2004, >
Edizione [1st ed.]
Pubbl/distr/stampa London, England : , : McGill-Queen's University Press, , [2022]
Descrizione fisica 1 online resource (305 pages)
Disciplina 362.295561
Collana Intoxicating Histories
Soggetto topico Cannabis - Government policy - Great Britain - History - 20th century
Cannabis - Government policy - Great Britain - History - 21st century
Cannabis - Therapeutic use - Great Britain - History - 20th century
Cannabis - Therapeutic use - Great Britain - History - 21st century
Marijuana industry - Great Britain - History - 20th century
Marijuana industry - Great Britain - History - 21st century
Soggetto non controllato ACMD
CBD
CBMPs
Cannabinoids
Griffith Edwards
INCB
MS
Sativex
Science
Sir William Paton
THC
World Health Organization
bio tech industry
boundary substance
cannabis oil
clinical trials
committees
drug policy
drugs
epilepsy
exchange
expert advice
illicit substances
industry
international agencies
knowledge
marijuana
misuse
oral history
patient access
pharmaceutical
pharmacology
phytopharmacy
plant based medicine
policy
pot
psychopharmacology
tinctures
uncertainty
user activism
ISBN 0-2280-1350-X
0-2280-1349-6
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Front Matter -- Contents -- Figures -- Acknowledgements -- Abbreviations -- Introduction -- Understanding Cannabis: Pharmacology, Laboratory Research, and Drug Control, 1964–82 -- Cannabis in the Clinic: Clinical Pharmacology and the Therapeutic Applications of Cannabis, 1973–82 -- Evidence-Based Policy? The Development of Expert Committees, 1972–82 -- Industrializing Cannabis: The Pharmaceutical Industry and the Remedicalization of Cannabis, 1973–2001 -- Forces of Necessity: Lay Advocacy and the Remedicalization of Cannabis, 1973–2001 -- Establishing Therapeutic Cannabis: The Role of Expert Advice, 1997–2001 -- From Anecdotal to Evidence-Based Medicine: The Role of Clinical Trials, 1995–2005 -- Accessing Cannabis-Based Medicinal Products, 2009–21 -- Conclusion -- Notes -- Bibliography -- Index
Record Nr. UNINA-9910810300903321
Taylor Suzanne <1909-2004, >  
London, England : , : McGill-Queen's University Press, , [2022]
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui